Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Marstrand, Troels Torben ; Borup, Rehannah ; Willer, A ; Borregaard, N ; Sandelin, Albin Gustav ; Porse, B T ; Theilgaard-Mönch, K. / A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. In: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2010 ; Vol. 24, No. 7. pp. 1265-75.

Bibtex

@article{c1193513e5004b32aad96b18da98ecc3,
title = "A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia",
abstract = "Chromosomal translocations of transcription factors generating fusion proteins with aberrant transcriptional activity are common in acute leukemia. In acute promyelocytic leukemia (APL), the promyelocytic leukemia-retinoic-acid receptor alpha (PML-RARA) fusion protein, which emerges as a consequence of the t(15;17) translocation, acts as a transcriptional repressor that blocks neutrophil differentiation at the promyelocyte (PM) stage. In this study, we used publicly available microarray data sets and identified signatures of genes dysregulated in APL by comparison of gene expression profiles of APL cells and normal PMs representing the same stage of differentiation. We next subjected our identified APL signatures of dysregulated genes to a series of computational analyses leading to (i) the finding that APL cells show stem cell properties with respect to gene expression and transcriptional regulation, and (ii) the identification of candidate drugs and drug targets for therapeutic interventions. Significantly, our study provides a conceptual framework that can be applied to any subtype of AML and cancer in general to uncover novel information from published microarray data sets at low cost. In a broader perspective, our study provides strong evidence that genomic strategies might be used in a clinical setting to prospectively identify candidate drugs that subsequently are validated in vitro to define the most effective drug combination for individual cancer patients on a rational basis.",
author = "Marstrand, {Troels Torben} and Rehannah Borup and A Willer and N Borregaard and Sandelin, {Albin Gustav} and Porse, {B T} and K Theilgaard-M{\"o}nch",
year = "2010",
month = "7",
day = "1",
doi = "10.1038/leu.2010.95",
language = "English",
volume = "24",
pages = "1265--75",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

RIS

TY - JOUR

T1 - A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia

AU - Marstrand, Troels Torben

AU - Borup, Rehannah

AU - Willer, A

AU - Borregaard, N

AU - Sandelin, Albin Gustav

AU - Porse, B T

AU - Theilgaard-Mönch, K

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Chromosomal translocations of transcription factors generating fusion proteins with aberrant transcriptional activity are common in acute leukemia. In acute promyelocytic leukemia (APL), the promyelocytic leukemia-retinoic-acid receptor alpha (PML-RARA) fusion protein, which emerges as a consequence of the t(15;17) translocation, acts as a transcriptional repressor that blocks neutrophil differentiation at the promyelocyte (PM) stage. In this study, we used publicly available microarray data sets and identified signatures of genes dysregulated in APL by comparison of gene expression profiles of APL cells and normal PMs representing the same stage of differentiation. We next subjected our identified APL signatures of dysregulated genes to a series of computational analyses leading to (i) the finding that APL cells show stem cell properties with respect to gene expression and transcriptional regulation, and (ii) the identification of candidate drugs and drug targets for therapeutic interventions. Significantly, our study provides a conceptual framework that can be applied to any subtype of AML and cancer in general to uncover novel information from published microarray data sets at low cost. In a broader perspective, our study provides strong evidence that genomic strategies might be used in a clinical setting to prospectively identify candidate drugs that subsequently are validated in vitro to define the most effective drug combination for individual cancer patients on a rational basis.

AB - Chromosomal translocations of transcription factors generating fusion proteins with aberrant transcriptional activity are common in acute leukemia. In acute promyelocytic leukemia (APL), the promyelocytic leukemia-retinoic-acid receptor alpha (PML-RARA) fusion protein, which emerges as a consequence of the t(15;17) translocation, acts as a transcriptional repressor that blocks neutrophil differentiation at the promyelocyte (PM) stage. In this study, we used publicly available microarray data sets and identified signatures of genes dysregulated in APL by comparison of gene expression profiles of APL cells and normal PMs representing the same stage of differentiation. We next subjected our identified APL signatures of dysregulated genes to a series of computational analyses leading to (i) the finding that APL cells show stem cell properties with respect to gene expression and transcriptional regulation, and (ii) the identification of candidate drugs and drug targets for therapeutic interventions. Significantly, our study provides a conceptual framework that can be applied to any subtype of AML and cancer in general to uncover novel information from published microarray data sets at low cost. In a broader perspective, our study provides strong evidence that genomic strategies might be used in a clinical setting to prospectively identify candidate drugs that subsequently are validated in vitro to define the most effective drug combination for individual cancer patients on a rational basis.

U2 - 10.1038/leu.2010.95

DO - 10.1038/leu.2010.95

M3 - Journal article

VL - 24

SP - 1265

EP - 1275

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -

ID: 32226022